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Abstract
The prostate cancer antigen gene 3 (PCA3) is embedded in an intron of a second gene BMCC1 (Bcl2-/adenovirus
E1B nineteen kDa-interacting protein 2 (BNIP-2) and Cdc42GAP homology BCH motif-containing molecule at the
carboxyl terminal region 1) which is also upregulated in prostate cancer. BMCC1 was initially annotated as two genes
(C9orf65/PRUNE and BNIPXL) on either side of PCA3 but our data suggest that it represents a single gene coding
for a high molecular weight protein. Here we demonstrate for the first time the expression of a >300 kDa BMCC1
protein (BMCC1-1) in prostate cancer and melanoma cell lines. This protein was found exclusively in the microsomal
fraction and localised to cytoplasmic vesicles. We also observed expression of BMCC1 protein in prostate cancer
sections using immunohistology. GST pull down, immunoprecipitation and mass spectrometry protein interaction
studies identified multiple members of the Adaptor Related Complex 2 (AP-2) as BMCC1 interactors. Consistent with
a role for BMCC1 as an AP-2 interacting endosomal protein, BMCC1 co-localised with β-adaptin at the perinuclear
region of the cell. BMCC1 also showed partial co-localisation with the early endosome small GTP-ase Rab-5 as well
as strong co-localisation with internalised pulse-chase labelled transferrin (Tf), providing evidence that BMCC1 is
localised to functional endocytic vesicles. BMCC1 knockdown did not affect Tf uptake and AP-2 knockdown did not
disperse BMCC1 vesicular distribution, excluding an essential role for BMCC1 in canonical AP-2 mediated endocytic
uptake. Instead, we posit a novel role for BMCC1 in post-endocytic trafficking. This study provides fundamental
characterisation of the BMCC1 complex in prostate cancer cells and for the first time implicates it in vesicle
trafficking.
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Introduction
Prostate cancer is a commonly diagnosed malignancy and a
leading cause of cancer deaths worldwide. This condition
exhibits a wide spectrum of histological changes and
behaviours, ranging from premalignant lesions, to localized
prostate cancers that follow an indolent course to a percentage
of cancers that metastasize early and progress rapidly [1].
Therefore, in addition to development of improved diagnostic
and prognostic tools, a detailed understanding of the cell
biology of prostate cancer development and progression is
required. One of the most promising biomarkers for prostate
cancer is the non-coding RNA PCA3 [2,3]. This RNA was
identified as a prostate cancer biomarker by differential display
analysis of RNAs from histologically normal and malignant
tissue from the same patients, and was originally described as
Differential Display clone 3 (DD3) [2]. High levels of PCA3
expression are strongly associated with malignant
transformation of the prostate epithelium, however, the
biological basis for this correlation has not been elucidated
[2–4].
We previously demonstrated that PCA3 is embedded in the
intron of another gene, BMCC1 [5]. BMCC1 was originally
annotated as two discrete genes c9orf65/PRUNE (coding for
N-terminal region) and BNIPXL (coding for C-terminal region).
A BNIPXL (BMCC1-4) open reading frame was identified by
database searching for homologues to the Bcl-2 interacting
protein BNIP-2 [6]. The authors identified BNIPXL/BMCC1-4 as
a gene with a region of high BNIP-2 homology, and named the
homologous region the BCH (BNIP-2/Cdc42GAP Homology)
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domain [6]. Using exogenously expressed tagged BNIPXL
proteins, they demonstrated that it interacts with RhoA and its
activator proto-Lbc [6]. Coexpression and interaction studies
demonstrated that BNIPXL binds RhoA and proto-Lbc via
different regions and that BNIPXL expression blocks RhoA
signalling, at least partially by inhibiting the stimulatory RhoA-
Lbc interaction [6]. Machida et al. [7] identified a longer isoform
of BMCC1 in human neuroblastoma (BMCC1-3), which
spanned coding exons 7-19 of the later identified BMCC1-1.
High levels of expression of this transcript were correlated with
a more favourable prognosis for this cancer. Evidence for the
expression of the full length BMCC1-1 transcript spanning the
c9orf65 and BNIPXL genes was provided by Iwama et al. [8],
who cloned a full-length cDNA from Hela cells. In this study
and subsequently, BMCC1 transcripts have been detected in
restricted regions of the mouse brain [8,9]. Clarke et al. [5]
demonstrated that BMCC1 RNA expression is elevated in
prostate cancer and metastases compared with benign tissue,
indicating that BMCC1 may be functioning differently in
different cancers and tissue types. An overview of BMCC1
isoform expression and the diverse functions of BCH domain
containing proteins is provided in recent publications [10,11].
Initial identification of a protein corresponding to BMCC1-1
was demonstrated by Iwama et al. [8]. This group raised an
antibody specific to the extreme N-terminal region of BMCC1-1,
and although multiple bands were detected by Western blot of
Hela MR, HEK293T and KNS81 glioma cells, only bands >250
kDa were sensitive to specific siRNA depletion. Mass
spectrometry was used to identify these high molecular weight
bands as BMCC1-1. In the same study, expression of
exogenous protein from a cDNA clone also produced multiple
bands on SDS-PAGE, probably indicating substantial
proteolysis, making interpretation difficult. More recently, Li et
al. [12] identified olfaxin proteins corresponding to alternative
BMCC1 transcription start sites expressed in the olfactory bulb,
with the predominant band at 52 kDa. Arama et al. [11]
detected a band of the same size in whole brain lysates and
cultured neurons and astrocytes, which they called BMCC1s. In
the present study, expression and initial characterisation of a
single 340 kDa BMCC1 protein in the prostate cancer cell line
LNCaP is described. The identity of this protein was robustly
established by detection with several antibodies to C- and N-
terminal regions of the protein, depletion by specific siRNA and
supported by MALDI TOF/TOF analyses. For the first time we
identified endogenous protein interactions involving a region
outside the BCH domain. We found that a BMCC1 region
without computationally identifiable functional domains
interacts with the Adaptor protein complex 2 (AP-2). We also
demonstrated co-localisation of BMCC1 with β-adaptin and
various endosomal markers, including Rab5 and internalised
transferrin (Tf). Preliminary functional analyses suggest
BMCC1 is a non-canonical AP-2 interacting protein involved in
post-endocytic trafficking.
Materials and Methods
Tissues and cell lines
Human prostate tissues were donated by patients at the
Royal Brisbane Hospital with written informed consent under
ethical approval of the Queensland Institute for Medical
Research human ethics committee. Patient consent forms have
been retained. Mouse tissues were obtained from a5 month old
wild-type male BalbC mouse, under ethical approval of the
Queensland Institute for Medical Research (QIMR) animal
ethics committee. LNCaP, 22Rv1, DU145, RWPE1, ALVA,
PC3 and MCF-7 were obtained from the ATCC. A11, D11,
D28, D33 and D38 were gifts from Chris Schmidts laboratory
(QIMR). These were obtained from patients enrolled in clinical
trials at QIMR, with written informed consent from the QIMR
human research ethics committee. A microarray study on the
cell lines A11 and D11 has been published [13], as has a
clinical study on the D-series patients [14]. All cell lines were
maintained in DMEM (Gibco) with penicillin and streptomycin,
supplemented with 10% heat inactivated foetal bovine serum
(Gibco).
RNA Extraction and cDNA Synthesis
Total RNA from cell lines and tissues was purified using
Trizol (Invitrogen) according to the manufacturers’ instructions.
This RNA was reverse transcribed into cDNA using Superscript
III (Invitrogen) according to the manufacturers’ instructions.
PCR and Generation of cDNA clones
cDNA clones of BMCC1 and other genes were generated by
amplification of the target from LNCaP cDNA. Oligonucleotides
were purchased from Sigma Aldrich, standard PCR
amplifications were performed wth Pfu Turbo (Roche). Typical
cycle conditions were 92°C 2 minutes followed by; 92°C for 30
sec, 60°C for 30 sec, 72°C for 90 sec/kb (2 cycles); 92°C for 30
sec, 57°C for 30 sec, 72°C for 90 sec/kb (2 cycles); 92°C for 30
sec, 53°C for 30 sec, 72°C for 90 sec/kb (30 cycles). All q-PCR
was performed using the Corbett Rotorgene-6000 (Qiagen,
Australia), Rotorgene-6000 Series Software (Qiagen, Australia)
and Quantitect® SYBR® Green PCR Kit (Cat. No. 204143,
Qiagen, Australia). Reactions were prepared in triplicate and
each contained 7.5µl of qPCR master mix, 0.5µl of each 10µM
forward and reverse primer and 5µl of diluted cDNA (1:10
dilution). Cycling condition for BMCC1 and β2M primers were
as follows: 95°C for 15 min, followed by 45 cycles of 95°C for
20 sec, 58°C for 20 sec and 72°C for 20 sec. Cycling
conditions for AP2M1 primers were as follows: 95°C for 15 min,
followed by 45 cycles of 95°C for 20 sec, 60°C for 20 sec and
72°C for 20 sec. Data were generated with the Rotorgene-6000
Series Software and relative gene expression levels were
calculated using methodology described in Pfaffl [15]. Primer
sequences and restriction sites are indicated in supplementary
material (Table S1). All restriction enzymes were purchased
from NEB.
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Recombinant protein expression, purification and
crosslinking
Recombinant protein expression and purification and
crosslinking were performed as previously described [16].
Antibodies
Recombinant BMCC1-GST fusion proteins were expressed
and purified as described above. The rabbit antibodies Ab-1
and Ab-3 were generated by injection of rabbits with eluted,
non-denatured GST fusion proteins (using the Institute for
Medical and Veterinary Science, Adelaide standard dose rate,
schedule and adjuvants). BMCC1 Ab-2 antiserum was
generated by inoculation of a rabbit with denatured GST fusion
protein embedded in unfixed polyacrylamide gel slices (IMVS).
BMCC1 sheep antiserum was generated by inoculation of a
sheep with eluted non-denatured BMCC1-GST fusion protein
(IMVS) (Ab-4). All proteins had N-terminal GST tags when
inoculated and the specific BMCC1 sequences for each
antibody are detailed in Table S1. Specific antibodies and non-
specific control antibodies were purified from serum as
described [16].
Commercial antibodies used in this project were mouse anti-
DNA PKcs (Santa Cruz product 18-2), mouse anti- RNA
polymerase II (Abcam, ab5408), rabbit anti-β-adaptin (which
detects AP-1B1 and AP-2B1) (Santa Cruz A-5), mouse anti-
EEA1 (BD Transduction Laboratories, 610457), mouse anti-α-
tubulin (Sigma T9026) and mouse anti-gapdh (Millipore
MAB374). Appropriate Alexafluor conjugated donkey
secondary antibodies were obtained from Invitrogen and HRP
conjugated secondary antibodies were from Sigma.
Plasmid and siRNA transfection
LNCaP were plated into 6 well dishes in antibiotic free
growth medium at least 48 h before transfection. Plasmids
were transfected into LNCaP using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions (2 µg
of plasmid and 5 µL of Lipofectamine 2000 per 9.5 cm2 well).
siRNA duplexes were purchased from Invitrogen (sequences in
Table S1) and transfected using Lipofectamine RNAiMAX or
Lipofectamine 2000 (100 pmol of siRNA duplex and 5 µL of
Lipofectamine per 9.5 cm2 well).
Generation of cell and tissue lysates
Cells were detached from their growth substrate by
trypsinization in serum free DMEM with 0.025% trypsin (Gibco),
and trypsin was inactivated by addition of DMEM containing
10% serum. Cells were pelleted by centrifugation (500 x g for 5
min) and washed twice in PBS. Washed cell pellets were then
lysed in ice-cold Mammalian Cell Lysis Buffer (MCLB, 50 mM
Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40). All lysates
contain a 2 x concentration of Roche Complete EDTA-free
protease inhibitor. Thorough washing to remove cell culture
trypsin and the addition of a high concentration of protease
inhibitors are critical to detect undegraded BMCC1, which is
otherwise subject to rapid proteolysis. Tissue lysates were
generated by homogenization in MCLB, by grinding in a Kontes
size 22 ground-glass dounce homogenizer. Cell and tissue
lysates were cleared by centrifugation (17,000 x g for 20 min at
4°C). Brain tissue lysates were subjected to additional
processing to remove a layer of floating lipids. Brain tissue
lysates were separated on to Biorad Micro Biospin desalting
chromatography columns which had been pre-equilibrated with
MCLB, which removed sticky insoluble material. Protein
concentrations were determined using the Biorad, Lowry
protein assay with BSA standards.
Western blotting
Samples in Laemelli SDS-PAGE loading buffer were
subjected to standard SDS-PAGE. Proteins were transferred
onto Amersham nitrocellulose in transfer buffer (6 g/L tris base,
3 g/L glycine, 0.36 g/L SDS, 20% methanol) for 100 V.h.
Membranes were blocked in blocking solution (PBS-0.05%
Triton-X100 with 5% BSA or PBS/0.07% Tween 20 with 4%
skim milk powder). Membranes were probed using between 0.2
and 5 ng/µL of the indicated antibodies in blocking solution at
ambient temperature for 2 h or 4°C overnight and detected
using HRP conjugated secondary antibodies and Western
Lightning luminol reagent (Pierce).
Immunoprecipitation and GST pulldowns
Cell lysates were generated as described above. For
immunoprecipitation, lysates were incubated with purified null
or BMCC1 antibodies (0.5-2 µg of antibody per mg of lysate) at
4°C overnight. BMCC1-antibody complexes were precipitated
by addition of protein G agarose resin for 2 h at 4°C. For GST
pulldowns, lysates were incubated with BMCC1-GST fusion
protein crosslinked resin at 4°C overnight. In both cases,
unbound proteins were washed from the resin in 3 x 20 bed
volume washes of cold lysis buffer. Precipitated proteins were
eluted by addition of 2 resin bed volumes of SDS-PAGE
loading buffer. Eluted proteins were then analysed by SDS-
PAGE and western blotting.
Mass Spectrometry
Silver stained gel pieces were destained in 15 mM potassium
ferricyanide and 50 mM sodium thiosulfate and washed in
water. Pieces were dehydrated in 25 mM ammonium
bicarbonate/ 50% acetonitrile and vacuum dried. They were
sequentially reduced and alkylated with 25mM DTT and 55mM
iodoacetamide, both in 25mM ammonium bicarbonate. Gel
pieces were dehydrated in 25 mM ammonium bicarbonate /
50% acetonitrile and dried again. They were then rehydrated
with 20ng/µL sequencing grade trypsin (Promega) in 40mM
ammonium bicarbonate/ 10% acetonitrile, topped up to prevent
drying and digested overnight at 37°C. Peptides were extracted
by washing the pieces in 0.1% TFA. Eluted peptides were
desalted using C-18 ZipTips (Millipore) according to the
manufacturers instructions. Peptides were then mixed with
MALDI matrix (Bruker) and analysed using Bruker Ultraflex in
positive ion reflector mode with a MS/MS tolerance of 100 ppm.
Analysis was performed in-house using Mascot, searching
against the 2012 mammalian non-redundant database,
allowing for default post-translational modifications and up to
one missed trypsin cleavage [17].
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Purification of microsomes
LNCaP cells were separated into nuclear and cytoplasmic
fractions by douncing in hypotonic solution as previously
described [16]. Microsomes were purified from cytoplasmic
extract by ultracentrifugation (100,000 x g for 1 h at 4°C using a
Beckman SW55Ti rotor). Microsomes were resuspended in
SDS lysis buffer (2% SDS, 1mM DTT, 125mM Tris pH 6.8) and
cleared at 17,000 x g for 20 min. Cytosol was concentrated to
1/10 its original volume using a 10K cut-off centrifugal filter unit
(Millipore) before SDS-PAGE.
Immunohistological staining
A standard immunohistochemistry staining procedure was
followed. Paraffin-embedded sections were cut at 4 µm and
were mounted on 5-aminopropyltriethoxysilane (AAS) coated
slides, which were then left to dry overnight. The paraffin-
embedded sections were dewaxed in xylene and were treated
with microwave heating at 60°C for 20 min in a citrate buffer
(2.1g/1000 ml; pH 6.0) for antigen retrieval. After blocking of
endogenous peroxidase, washing in phosphate-buffered saline
(PBS) and blocking of non-specific binding of secondary
antibody with normal swine serum, routine streptavidin-biotin-
peroxidase immunostaining with diaminobenzidine was
applied. The sections were incubated overnight in BMCC1
Ab-3. The primary antibody was substituted with PBS in
sections used as negative controls. The sections were
counterstained with Harris Haematoxylin. Since BMCC1 is
known to be positive in benign prostatic tissues, a core of
prostate tissue with benign hyperplasia was included as a
positive control in each of the array.
Scoring of the BMCC1 protein expression within the cells of
the tissues of the 74 patients studied, was based on the
proportion of cells stained with the BMCC1 polyclonal antibody
and the intensity of the stain within the cells. Staining intensity
was scored on the following scale: No staining, mild, moderate
and strong. All the samples were analysed under microscopic
examination using an Olympus microscope (Model: BX40), at a
magnification of x200.
Immunofluorescence and microscopy
Cells were seeded onto sterile coverslips at least 24 h before
fixation. Media was aspirated and cells were washed once in
PBS before crosslinking (in PBS with 10% foramlin for 10 min
at room temperature). The fixative was removed and cells
washed in PBS before permeabilization and blocking in PBS
with 0.05% Triton-X100 and 5% FBS. Cells were then stained
with between 0.4 and 2 ng/µL of the indicated primary
antibodies at ambient temperature for 2 h or 4°C overnight.
Species matched purified IgG was employed as an appropriate
control for antibody crossreactivity/adsorption. All antibodies
were detected using appropriate Alexafluor488 or Alexafluor
594 donkey secondary antibodies. Confocal microscopy was
carried out on a Zeiss LSM710. Co-localisation was quantified
using Zen 2011 software. Overlap coefficient/overlap
coefficient after Manders, a method insensitive to differences in
signal intensity, was used to quantify co-localisation in image
pairs.
Transferrin uptake
LNCaP were seeded onto sterile coverslips 24h before the
labelling. Pulse-chase uptake of a conjugated transferrin-
receptor complex (Tf-R) was performed essentially as
described by Aschenbrenner et al. [18]. Briefly, cells were
serum starved in serum free media (phenol-red free DMEM-
F12, Life Technologies) for 2 h at 37°C. To surface label cells
with conjugated transferrin, cells were placed on ice for 30 min
then incubated with 20µg/ml Alexafluor-594 conjugated
transferrin (Molecular Probes) diluted in ice-cold serum free
media for 30 min. Cells were washed twice with ice-cold serum
free media to remove unbound transferrin and t=0 coverslips
were harvested for BMCC1 immunofluorescence, as described.
The remaining coverslips were chased in pre-warmed serum
free media for the indicated time periods before harvest.
Uptake of conjugated transferrin-receptor complex was also
performed using a method similar to Boucrot et al. [19]. Cells
were rinsed once with DMEM-F12/5%FCS then incubated for
10 min with 10µM Alexafluor-594 conjugated transferrin in
DMEM-F12/5% FCS. Cells were then washed with ice cold
PBS before being harvested for immunofluorescence.
Results
BMCC1-1 protein is expressed in select cancers
hBMCC1 is a large and complex transcriptional unit, with the
routinely used prostate cancer biomarker hPCA3 embedded in
BMCC1 intron 6. BMCC1 has been previously annotated as
discrete PRUNE2 and BNIP genes flanking PCA3, with
exogenous expression based studies reflecting this. Recent
results have shown that BMCC1 produces a transcript
(denoted BMCC1-1) which extends across the embedded
antisense PCA3 gene [5,8]. Here we demonstrate that the
BMCC1-1 RNA is expressed in 10/10 PCA3 positive prostate
cancer tissue samples (Figure S1).
We have previously shown that the prostate cancer cell line
LNCaP expresses high levels of both BMCC1-1 and PCA3
RNAs [5]. To extend these studies to endogenous BMCC1
protein, we generated several polyclonal antibodies using
recombinantly expressed fragments of BMCC1 as antigens
(schematic in Figure S2, cloning primers in Table S1). These
antibodies were employed to demonstrate that BMCC1
produces a >300 kDa protein in LNCaP (Figure 1). The size of
this protein corresponds to that predicted from the BMCC1-1
cds and translated peptide sequence (ie 3088 amino acids,
~340 kDa). The 340 kDa BMCC1 protein was detected with
both C-terminal Ab-1 (raised against amino acid 2345-2705)
and N-terminal Ab-3 (raised against amino acid 1-369) in
LNCaP cells. Expression of this protein was not detected in the
PCA3 negative prostate cancer cell lines PC3, DU145, ALVA,
RWPE-I (Figure 1A). BMCC1 expression was also absent from
the PCA3 negative breast cancer cell line MCF7. BMCC1 was
not detected in normal cells as we have previously reported [5].
The identity of the 340 kDa band was confirmed by
immunoprecipitation of BMCC1 from LNCaP extracts using
Ab-3, followed by Western blot detection with Ab-2 (raised
against amino acid 222-276) (Figure 1B). The specificity of
BMCC1 detection was further confirmed by transient depletion
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of BMCC1 expression by siRNA and detection with multiple
antibodies. BMCC1 siRNA transfection caused a dramatic
reduction in the intensity of the 340 kDa protein band detected
by both C- and N- terminal antibodies Ab-1 and Ab-3 (Figure
1C). This supports the immunoprecipitation data to robustly
demonstrate that BMCC1 is a protein coding gene, producing a
340 kDa protein in the PCA3 expressing cell line LNCaP. We
did not detect expression of siRNA sensitive anti-BMCC1
reactive bands at lower molecular weights, indicating that the
BMCC1-1 protein is the predominant gene product in prostate
cancer cells (data not shown). BMCC1 protein expression was
not detected in several cell lines derived from neuroblastoma,
breast and ovarian carcinoma (data not shown). BMCC1
protein was detected in 3/5 primary melanoma cell lines, and in
some cases a doublet was observed (Figure S3). The identity
of the bands in melanoma cell lines was demonstrated robustly
by detection of BMCC1 with antibodies to different regions of
the protein, Ab-1 and Ab-3. This indicates that BMCC1 could
have a role in other tumour types.
Machida et al. [7] and Li et al. [12] used in situ hybridization
of mouse embryos to show that BMCC1 RNA is expressed
predominantly in neuronal tissue, and Zhou et al. [20] used
PCR of mouse tissue RNA to show that at least the BCH
domain is expressed in a range of tissue types. Iwama et al. [8]
used PCR primers spanning the whole gene to demonstrate
strong expression in the dorsal root ganglion with intermediate
expression in the whole brain, spinal cord, prostate and uterus
and low expression in other tissues. To address this
discrepancy of constitutive versus restricted RNA expression,
and to obtain additional information about protein expression
and putative spliced gene products, we immunoblotted protein
lysates from a panel of adult mouse tissues using BMCC1
Ab-4. In this non-tumourigenic setting we detected a strong ~80
kDa band in brain tissues, with lower expression of a smaller
72 kDa band (Figure S4). The 52kDa BMCC1s identified by
Arama et al. [11] was not observed here because the antigen
for Ab-4 spans amino acids 2192-2433 of BMCC1-1 and does
not contain any portion of BMCC1s (see Figure S2). To confirm
expression of BMCC1 in a prostate cancer tumour setting,
immunohistological staining of prostate cancer tissues was
performed using Ab-3. Minimal BMCC1 staining was observed
in benign prostate hyperplasia glandular epithelium and
stroma, with stronger staining observed in the glandular
epithelium of prostate tumours (Figure S5).
BMCC1 interacts with AP-2 in prostate cancer cells
In order to gain insight into the cellular function of BMCC1,
interacting proteins were identified by purification with BMCC1-
GST affinity resins. We generated a series of overlapping
BMCC1-GST clones in pGEX that cover the full-length cDNA
(Table S1). Recombinant proteins were expressed and
crosslinked to glutathione agarose to generate a series of
affinity matricies for interacting proteins. Crosslinked GST-
BMCC1 fusion resins were incubated with total LNCaP lysate
to purify BMCC1 interactors. Resin associated proteins were
eluted, resolved and visualised by silver stained SDS-PAGE.
BMCC1 GST fragments 1-2 and 4-10 pulled down a range of
proteins frequently identified as non-specific or non-functional
interactors. These include eEF1γ, 40S ribosomal protein,
GRP75 and GRP78 (data not shown). BMCC1 GST F3 (amino
acids 575-904) precipitated specific bands at 50 kDa and 110
kDa (Figure 2A). The 50 kDa and 110 kDa interacting bands
were excised and identified by mass spectrometry (MALDI
MS/MS on a Bruker Ultraflex III). A summary of Mascot search
data is shown in Table S2. This revealed that BMCC1-F3
interacts with several members of the Adapter Related protein
Complex 2 (AP-2). The AP-2 complex is an endosome
associated heterotetramer consisting of three different
constitutive components (AP-2S1, AP-2M1 and AP-2B1/β-
adaptin) and one of two mutually exclusive components
(AP-2A1 or AP-2A2) [21]. The 50 kDa BMCC1-F3 interacting
protein was identified as AP-2M1, based on two separate
identifications with a total of 8 non-redundant peptides (Table
S2). The 110 kDa BMCC1 interacting band contained a mixture
of three high molecular weight AP-2 complex members:
AP-2A1, AP-2A2, and AP-2B1 (Table S2). AP-2B1 was
identified in two samples with a total of 5 unique peptides. The
homology between AP-2A1 and AP-2A2 makes individual
unique identifications complex (Figure S6). AP-2A1 was
identified in 3 samples with a total of 6 peptides that do not
correspond to AP-2A2. AP-2A2 was identified in one sample
with one peptide not attributable to AP-2A1. In these samples,
three individual peptides could have corresponded to either
AP-2A1 or AP-2A2 and cannot be attributed with certainty to
one or the other due to sequence identity (Table S3). No
computationally identifiable domains could be attributed to this
region, so functional interaction mapping of BMCC1 has
identified a novel protein–protein interaction motif. The
interaction between BMCC1 and the AP-2 complex was
confirmed by co-immunoprecipitation. BMCC1 was
immunoprecipitated from LNCaP lysates and the resulting
interacting proteins were eluted and analysed by Western
blotting (Figure 2B) revealing that endogenous BMCC1
interacts with β-adaptin and AP-2A1/2 (Figure 2B). The
endogenous interaction between BMCC1 and the AP-2
complex was further substantiated by BMCC1
immunoprecipitation from lysates of cells which had been
BMCC1 depleted with siRNA. A 340 kDa band was detected on
the high molecular weight resolving Coomassie stained gel
(Figure 2C). This band was of reduced intensity in the
immunoprecipitate from BMCC1 depleted cells compared to
the control siRNA cells. Although immunoprecipitation is not a
quantitative approach, this reduced intensity guided band
selection for subsequent MS analysis. The identification of this
band as BMCC1 was confirmed by MALDI-TOF/TOF of tryptic
peptides from the excised gel slice. Importantly, the extreme
BMCC1 N-terminal peptide TEFNYFTETR, not present in the
truncated isoform (BMCC1-3) reported by Machida et al. [7]
was identified among these (Table S4). This provided de novo
evidence of BMCC1-1 protein expression in LNCaP cells. The
interaction profile of BMCC1 was examined by Western blotting
these immunoprecipitates for AP-2A1/2 and β-adaptin.
Consistent with the reduced level of BMCC1 protein in the
siBMCC1 immunoprecipate, reduced signals for AP-2A1/2 and
β-adaptin were detected in the precipitate from siBMCC1 lysate
than control lysate. This provided further evidence that these
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PLOS ONE | www.plosone.org 5 September 2013 | Volume 8 | Issue 9 | e73880
Figure 1.  hBMCC1 produces a 340kDa protein.  A. BMCC1 immunoblot of total cell extracts. 30 µg of lysate per cell line was
subjected to 5% SDS-PAGE. BMCC1 expression was detected using a rabbit antibodies raised against aa 2345 to 2705 (C-
terminal, rabbit anti BMCC1, Ab-1) and a second antibody, Ab-3 that recognises the N-terminus of BMCC1. DNA PKcs was used as
a loading control.
B. Immunoprecipitation of BMCC1 from LNCaP total lysate. BMCC1 was immunoprecipitated by incubation of 1 mg of LNCaP
lysate with 1 µg of Ab-3 for 8 h at 4°C followed by precipitation with protein G agarose. Non-specific (NS) IgG was used in place of
Ab-3 in a control IP. Washed resin was eluted in SDS-PAGE loading dye and western blotted. The IgG heavy chain (loading)
demonstrates equal antibody input.
C. Depletion of BMCC1 expression by siRNA. LNCaP cells were transfected with BMCC1 siRNA 1730 (siBMCC1) or control
siRNA (siControl). Total lysate was harvested 3 days post-transfection and BMCC1 expression analysed by western blotting with
BMCC1 Ab-1 (C-terminal) and Ab-3 (N-terminal). The blot was completely stripped between sequential probes. RNA polymerase II
is a loading control.
doi: 10.1371/journal.pone.0073880.g001
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proteins specifically interact with BMCC1 (Figure 2C). We have
not explored the interaction between BMCC1 and AP-2M1 by
immunoprecipitation due to the size similarity between AP-2M1
and the IgG heavy chain, and the lack of availability of quality
AP-2M1 antibodies. However, AP-2M1 is a constitutive
component of the AP-2 complex and BMCC1’s demonstrated
interaction with both A/α and B/β AP-2 subunits indicates that
AP-2M1 would also be present.
BMCC1 co-localises with endocytic vesicles at various
stages of biogenesis
The subcellular distribution of BMCC1 in LNCaP was
investigated using immunofluroescence with N- and C- terminal
antibodies. BMCC1 displayed granular cytoplasmic staining
with both antibodies (Figure 3A). High resolution confocal
immunofluorescent analysis of BMCC1 localisation using two
different BMCC1 antibodies displayed strong overlap,
indicating that both antibodies detect the same protein (Figure
3B). This analysis revealed that BMCC1 is present in small
vesicles, which are present throughout the cytoplasm and
particularly concentrated in the juxta-nuclear region. The
specificity of BMCC1 immunostaining was further confirmed by
depletion of BMCC1 immunostaining in LNCaP cells
transfected with BMCC1 siRNA (Figure 3C). Control
transfected cells have a range of BMCC1 expression levels by
immunostaining (Figure 3C, upper panel). Consistent with
strong BMCC1 depletion observed by western blotting (Figure
1C), BMCC1 stained cells are infrequent after transfection with
siBMCC1 (Figure 3C, arrow) and most cells are completely
negative. BMCC1 immunostaining of aphidicolin synchronized
LNCaP cultures revealed that the expression and distribution of
BMCC1 is independent of cell cycle phase (Figure S7). The
Figure 2.  BMCC1 protein interaction mapping.  A. Purification of BMCC1 interacting proteins. Crosslinked BMCC1 GST
fragment 3 was used as bait to purify interacting proteins. GST crosslinked resin is a non-specific binding control. Interacting
proteins were analysed by silver-stained SDS-PAGE. BMCC1-F3 interacting proteins were excised from the silver stained gel,
processed and identified by MALDI TOF/TOF. Band identities are indicated.
B. Immunopurification of BMCC1 and interacting proteins. Sheep anti-BMCC1 Ab-4 or nonspecific (NS) sheep IgG were
incubated with LNCaP total lysate overnight and complexes were precipitated with protein G agarose. Immunoprecipitates were
subjected to immunoblot using antibodies specific for BMCC1 (Ab-1), β-adaptin and AP2A1/2 as indicated. IgG (loading) indicates
equal antibody input.
C. Immunopurification of BMCC1 and interacting proteins, using MALDI MS/MS identification. 80% confluent T-75s of LNCaP
cells were harvested 3 days post-transfection with control siRNA (siControl) or BMCC1 siRNA (siBMCC1). Clarified lysates were
immunoprecipitated with Ab-4 and analysed by Coomassie stained 5% gel or western blotting duplicate 5-15% gels for AP-2A1/2
and β-adaptin. IgG (loading) indicates equal antibody input. Immunoprecipitated BMCC1 was excised from the Coomassie gel and
its identity was confirmed by MALDI MS/MS (this particular Coomassie gel has been Gamma-curve adjusted for visual clarity and
corresponds to MALDI data Sample A in Supp Table 4).
doi: 10.1371/journal.pone.0073880.g002
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distribution of BMCC1 throughout the cytoplasm was further
investigated by separation of cytoplasmic vesicles from whole
cytoplasm, yielding cytosolic and microsomal fractions. BMCC1
was detected exclusively in the microsomal fraction, indicating
that BMCC1 is strongly vesicle associated (Figure 3D).
The granular cytoplasmic distribution of BMCC1 and its
constitutive interaction with the AP-2 complex led us to explore
co-localisation between BMCC1 and AP-2 proteins. LNCaP
cells were fixed and stained for BMCC1 three days after
transfection with AP-2M1 or AP-2B1 pEGFP constructs or
vector control. Substantial co-localisation was observed
between BMCC1 and AP-2M1 and AP-2B1 (Figure 4A).
AP-2M1-GFP displayed a cytoplasmic tubulovesicular structure
with small vesicles associated with the cell periphery and larger
structures in the peri-nuclear region. BMCC1 was associated
with the larger juxta-nuclear AP-2M1 labelled vesicles, but was
less abundant in the small peripheral vesicles closely
associated with the plasma membrane (Figure 4A, upper
panel). BMCC1 staining of AP-2B1-GFP transfected cells
revealed that BMCC1 and AP-2B1 partially co-localize and are
present on the same vesicles (Figure 4A, lower panel). The
substantial difference in localisation of BMCC1 and AP-2
complex members between AP-2B1 and AP-2M1-GFP
transfected cells probably represents aberrant localisation of
AP-2M1-GFP. The high level of exogenous expression
required to detect the GFP proteins by confocal microscopy
could cause abnormal localisation or changes in endocytic
function [22]. As such these data support the interaction/co-
localisation of BMCC1 and AP-2 but occur under conditions of
abnormal vesicular morphology. Therefore the localisation of
BMCC1 and the AP-2 complex was subsequently explored
using β-adaptin immunostaining of endogenous protein. Co-
staining with anti-BMCC1 and β-adaptin confirmed the juxta-
nuclear co-localisation of BMCC1 and the adaptor related
protein complex (Figure 4B, upper panel). A line profile through
the boxed region, in the peri-nuclear region of the cell, shows
overlapping fluorescence signals for BMCC1 and β-adaptin. A
circle was drawn around this region to generate the co-
localisation scatterplot and an overlap coefficient of 0.92 was
calculated using Zen 2011 analysis software (x axis = green
fluorescence, y axis = red fluorescence) (Figure 4B, lower
panel). Taken together, the co-staining and GFP co-localisation
data indicate that the AP-2 complex and BMCC1 coat
endosomes in the cell periphery and juxta-nuclear regions.
BMCC1 appears to be associated weakly with the early, more
peripheral endosomes and more strongly with tubulovesicular
structures adjacent to the nucleus.
In order to further characterise the specific vesicle type
BMCC1 is associated with, we also tested BMCC1 co-
localisation with the small GTPase Rab5. Rab5 is present on
primary endocytic structures but is most abundant on early
endosomes where it regulates the activity and recruitment of
downstream effectors prior to additional homotypic and
heterotypic fusion [23]. LNCaP cells were transfected with
GFP-Rab5a prior to staining with anti-BMCC1. Rab5a-GFP
transfected cells display substantial areas of co-staining
between BMCC1 and Rab5a (Figure 4C, upper panel). We also
employed a GTP-ase deficient form of Rab5 (Q79L) which
induces formation of enlarged early endosomes and also
enlarged multivesicular endosomes [24]. LNCaP cells
transfected with Rab5 Q79L showed large ring-like structures
that co-stained for BMCC1 and Rab5a (Figure 4C, lower
panel). While Rab5a and BMCC1 co-localisation was evident,
many vesicles were positive for one protein or the other. This
indicates that BMCC1 is present on a subset of sorting
endosomes only and constitutes more than one vesicle type.
As further proof of the presence of BMCC1 in early sorting
endosomes we showed minor co-localisation and juxta-position
of BMCC1 with the early endosome marker EEA1 (Figure S8).
Many BMCC1 positive vesicles were EEA1 negative, again
supporting the presence of BMCC1 on other vesicle types/at
other stages of endosomal biogenesis. EEA1 is specifically and
strongly associated with the early sorting endosome and is not
observed in other compartments or at other stages of endocytic
processing, in direct contrast to most other endocytic proteins,
including Rab5 [25]. The stronger overlap between BMCC1
and Rab5 staining could indicate that many EEA1 negative
BMCC1 vesicles could still be Rab5 positive.
We next explored co-localisation of BMCC1 with
Alexafluor594 conjugated transferrin (Tf). The transferrin-
receptor complex (Tf-R) is processed through early endosomes
and targeted to the recycling compartment of the endosome. In
pulse-chase experiments, labelled Tf did not immediately co-
localise with BMCC1. BMCC1 began to show some co-
localisation with conjugated Tf by the 2 min chase time point
and strong co-localisation by 30 min (Figure 5). Co-localisation
of BMCC1 with Tf at the early time point is consistent with the
presence of BMCC1 on early sorting endosomes, while the
strong co-localisation at later stages of uptake suggests that
BMCC1 persists on recycling endosomes.
BMCC1 and trafficking
Receptor mediated endocytosis of transferrin is heavily
dependent on the AP-2 complex. Depletion of the constitutive
µ/M subunit causes a ~90% reduction in the efficiency of
endocytosis of the transferrin receptor, but does not affect
internalization of EGF or LDL [26]. This suggests that while
AP-2 is necessary for endocytosis of some receptors, other
cargo molecules are able to utilize an alternative endocytic
mechanism. The interaction and co-localisation of BMCC1 with
the AP-2 complex, combined with the localisation of BMCC1 to
functional Tf transporting vesicles points to a possible role for
BMCC1 in vesicle trafficking. To begin to address this, we
examined the effects of BMCC1 depletion on Tf uptake. In cells
transfected with control siRNA, punctate staining of internalised
Tf was observed following a 10 min uptake, and co-localisation
with BMCC1 was evident (data not shown). In cells treated with
BMCC1 siRNA, normal BMCC1 staining was observed in ~20%
of cells, which is consistent with the knockdown efficiency of
70-80% we measured by qPCR (qPCR data not shown). In
these cells, co-localisation of BMCC1 and Tf was evident
(Figure 6A, white arrows). In cells with strongly depleted levels
of BMCC1, Tf levels, uptake and distribution remained
undisturbed (Figure 6A). Further analysis of BMCC1 roles in Tf
trafficking were impeded by the fact that membrane-bound Tf
must be removed by acid wash in order to measure recycling
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Figure 3.  Cellular distribution of BMCC1.  A. BMCC1 distribution in LNCaP. BMCC1 was labelled by immunostaining with
rabbit anti-BMCC1 antibodies to the C- or N- (Ab1, Ab2) terminus or non-specific (NS) rabbit antibody and detected with donkey
anti-rabbit Alexafluor 594. Cells were counterstained with Hoechst. Staining was analysed by wide-field fluorescent microscopy
(x63).
B. High resolution imaging of BMCC1 in LNCaP. Fixed LNCaP were incubated with a rabbit anti-BMCC1 (Ab-1) and a sheep
anti-BMCC1 (Ab-4). Cells were stained with donkey anti-rabbit Alexafluor 488 and donkey anti-sheep Alexafluor 594. Staining was
analysed by confocal fluorescent microscopy.
C. Ablation of BMCC1 immunostaining by siRNA. LNCaP were transfected with BMCC1 siRNA 1730 (siBMCC1) or control
siRNA (siControl) using Lipofectamine RNAiMAX. Cells were fixed 3 days post transfection and stained with rabbit anti-BMCC1
(Ab-1) and detected using donkey anti-rabbit Alexafluor 594.
D. Subcellular fractionation of LNCaP. LNCaP cytoplasmic extract was generated by dounce homogenization in hypotonic
solution and sedimentation of nuclei. Microsomes were precipitated from the recovered cytoplasm by ultracentrifugation. BMCC1
compartmentalization was analysed by western blotting the resulting microsomal and cytosolic fractions using antibodies against
BMCC1 (Ab-4) (5% gel), β-adaptin and α-tubulin (microsomes) and GAPDH (cytosolic) (duplicate 12% gel).
doi: 10.1371/journal.pone.0073880.g003
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Figure 4.  BMCC1 is endosomal.  A. Co-localisation of BMCC1 and endosomal reporter proteins. LNCaP were transfected
with pEGFP-AP-2M1 or pEGFP-AP-2B1. BMCC1 protein was detected using rabbit anti-BMCC1 (Ab-1) and donkey anti-rabbit
Alexafluor 594 72 h post-transfection. Localisation was analysed by confocal microscopy (100 x objective). Scale bars are 10 µm.
B. Co-localisation of BMCC1 with β-adaptin. LNCaP were fixed and stained with sheep anti- BMCC1 (Ab-4) and mouse anti-β-
adaptin. Proteins were detected with donkey anti-sheep Alexafluor594 and donkey anti-rabbit Alexafluor488. Cells were
counterstained with DAPI and analysed by confocal microscopy (63 x objective). Scale bar is 10 µm. The line profile shows
overlapping fluorescence signals for BMCC1 and β-adaptin and was generated by drawing a horizontal line through the boxed area
in the perinuclear region of the cell using Zen 2011 analysis software. A circle was drawn around the same area to generate the co-
localisation scatterplot and overlap coefficient data using Zen 2011 analysis software (x axis = green fluorescence, y axis = red
fluorescence).
C. Co-localisation of BMCC1 and Rab5. Cells were transfected with pEGFP-Rab5a (upper panel) or pEGFP- Q79L Rab5a (lower
panel). BMCC1 was detected using rabbit anti-BMCC1 (Ab-1) and donkey anti-rabbit Alexafluor 594, 24h post-transfection. Stained
cells were mounted in Prolong Gold containing Dapi and examined by confocal microscopy (63x). Scale bars are 10 µm.
doi: 10.1371/journal.pone.0073880.g004
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efficiency/clearance. Unfortunately, acid rinses distorted and
reduced BMCC1 staining (data not shown) making it
impossible to measure recycling in BMCC1 knockdown cells
only.
We used another approach to further investigate BMCC1
roles in trafficking. The AP-2 complex is a protein hub central to
the formation of endosomes. It interacts with the cell
membrane and cell membrane-associated cargo proteins as
well as with accessory proteins which are essential for
invagination and budding of endosomes [21]. Importantly,
knockdown of AP-2 has been shown to moderately disrupt the
vesicular localisation of accessory proteins [26,27]. Moreover,
Figure 5.  BMCC1 and transferrin co-localisation.  Co-localisation of BMCC1 and pulse-chase labelled transferrin. LNCaP
cells were coated with Alexafluor594 conjugated transferrin in ice-cold serum free media for 30 min and fixed at the indicated chase
times. Cells were BMCC1 immunostained with Ab-4, detected with Alexafluor488 and mounted in Prolong Gold with Dapi (63x
confocal). Arrows indicate areas of BMCC1 and transferrin co-localisation. Scale bars are 10 µm.
doi: 10.1371/journal.pone.0073880.g005
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Figure 6.  BMCC1 and vesicle trafficking.  A. BMCC1 is not required for transferrin uptake. LNCaP cells were tranfected with
siRNA 1730 to knockdown BMCC1. Cells were subjected to a 10 min pulse with Alexafluor594 conjugated transferrin, 48 h post-
transfection. Cells were then rinsed with ice-cold PBS to remove excess conjugate before fixation. Cells were BMCC1
immunostained with Ab-4, detected with Alexaflour 488 and mounted in Prolong Gold with Dapi (63x confocal). Scale bars are 10
µm.
B. BMCC1 vesicular localisation is independent of AP-2. LNCaP cells were subjected to two subsequent 48 h transfections with
siRNA s3112 to knockdown AP2-M1. Cells were then subjected to a 10 min pulse with Alexafluor594 conjugated transferrin. Cells
were then rinsed with ice-cold PBS to remove excess conjugate before fixation. Cells were BMCC1 immunostained with Ab-4,
detected with Alexafluor 488 and mounted in Prolong Gold with Dapi (63x confocal). White arrows indicate areas of BMCC1 and
transferrin co-localisation, while the yellow arrow highlights a cell displaying typical BMCC1 vesicular localisation in the absence of
functional AP-2. Scale bars are 10µm.
doi: 10.1371/journal.pone.0073880.g006
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specific cargo (Tf) uptake is dependent on AP-2 [26]. Since
BMCC1 interacts with AP-2 and co-localises with AP-2 and Tf,
we sought to determine if AP-2 is required for BMCC1 vesicular
localisation and/or formation. To deplete the AP-2 complex in
LNCaP cells we used AP-2M1 siRNA. We attained an average
of 88% knockdown efficiency for AP2-M1 in these experiments
(measured by qPCR, data not shown) and functional depletion
of the AP-2 complex was assessed via the inability of cells to
uptake labelled Tf. Cells transfected with control siRNA showed
normal punctate staining for internalised Tf (red), and co-
localisation with BMCC1 (green) was once again observed
(Figure 6B, upper panel, white arrows). Following AP-2M1
siRNA knockdown, Tf uptake was inhibited and it remained
trapped at the membrane (red staining) which indicated
successful depletion of functional AP-2 complexes. In these
depleted cells, neither BMCC1 vesicular localisation nor
number of vesicles was apparently disturbed (Figure 6B, lower
panel). The yellow arrow highlights one cell with functionally
depleted AP-2 complexes and typical BMCC1 staining. These
data suggest that even though BMCC1 and AP-2 interact and
co-localise, BMCC1 is not an archetypal AP-2 accessory or
cargo protein and BMCC1 vesicle formation does not depend
on AP-2. Instead, BMCC1 is a novel endosomal protein which
must interact with AP-2 during post-endocytic uptake trafficking
stages.
Discussion
This study provides persuasive evidence for the expression
of a high molecular weight form of BMCC1 protein in prostate
cancer and melanoma cell lines. We established BMCC1 as an
AP-2 interacting protein that is localised to endocytic vesicles.
The results concur with and extend earlier expression studies
on full-length mRNA and protein for BMCC1. Iwama et al. [7,8]
cloned a full-length cDNA and used immunoblotting to identify
a BMCC1 (PRUNE2) 338kDa protein. Here we developed
several antibodies to different regions of BMCC1 and used
these in combination with siRNA and MALDI MS/MS to provide
conclusive evidence for the expression of the high molecular
weight BMCC1 protein. Doubt existed on the extent of tissue
expression of BMCC1 protein isoforms since initial studies
were based on PCR [6,20]. Machida et al. [7] used semi-
quantitative RT-PCR to describe widespread expression of
BMCC1 in tissues including the nervous system and variable
expression in a variety of tumour cell lines. Use of in situ
hybridization by Li et al. [9] indicated that expression was high
in developing neuronal tissues. Arama et al. [11] demonstrated
expression of a 52 kDa BMCC1s protein in neurones, which a
follow-up study by Li et al. [12] supports. The results described
here reveal BMCC1 protein expression in the cerebellum and
cerebrum of adult mouse tissue lysates, with the predominant
band at approximately 80 kDa. While both Li et al. [12] and
Arama et al. [11] found that the predominant BMCC1 protein
expressed in their brain samples was 52 kDa, both studies also
detected a band of approximately 75 kDa. Differences in the
relative intensity of detected bands in our studies may be due
to the differing ages of our animals and antibody target regions.
Subsequent characterisations of tissue specific expression
could utilize the RNA segment corresponding to these antibody
targets as starting points for RACE-PCR.
One approach to understand the function of BMCC1 is to
identify interacting proteins. Soh and Low [6] identified BNIPXL
as a putative BNIP2 and Cdc42GAP (BCH) domain protein,
769 amino acids in length, corresponding to a C-terminal
region of the BMCC1 protein described here. They showed that
a recombinant form of this protein interacted with and inhibited
the activity of the small GTPase, Rho A. Signalling through
RhoA regulates actin dynamics, cellular morphogenesis and
motility [28]. More specifically, signalling through this protein is
linked to neuronal migration, growth cone collapse, dendritic
branching, neurodegeneration and cancer [29,30]. BMCC1/
PRUNE2 was identified in a large scale purification of GTP and
8-oxo-GTP binding proteins [8]. The same study identified T-
cell activation Rho GTPase activating protein as a binding
partner of BMCC1/PRUNE2, albeit with a low confidence
score. The latter data suggest that BMCC1 (PRUNE2) may be
interacting with GTP-signalling proteins to alter their activity.
Arama et al. [11] recently found that the 52 kDa brain specific
isoform of BMCC1 localized to microtubules and interacted with
the microtubule stabilizing protein MAP6/STOP [31]. This
BMCC1 isoform blocked the interaction of MAP6 and
microtubules, which inhibited microtubule stabilization and
changed cell morphology [11]. They showed punctiform
localisation of this 52kDa BMCC1 isoform to microtubules, but
the striking vesicular localisation presented in our study was
not evident [11]. This is not surprising given that the AP-2
interaction domain characterised herein is not present in the
shorter brain-specific isoform. In a recent follow-up study,
BMCC1s was shown to interact with kidney-type glutaminase,
a mitochondrial enzyme which converts glutamine to glutamate
in neurons [32]. Over-expression of BMCC1s induced re-
localisation of mitochondrial KGA to the cytoplasm. The
authors proposed a mechanism whereby BMMC1s indirectly
influences trafficking of KGA through destabilisation of
microtubule networks [32].
In the present study, we employed GST-pulldowns to identify
several members of the endosome-associated AP-2 complex
as binding partners for BMCC1 with reproducible, very high
confidence scores. The AP-2 complex is an adaptor in clathrin-
mediated endocytosis [33]. This complex associates with
phosphoinositides, clathrin and other membrane proteins to co-
ordinate cargo recruitment for internalisation, as well as
accessory proteins which mediate the structural formation of
endsomes [21]. The incoming cargo is received by early
endosomes which act as a sorting station in the endocytic
pathway [34]. In this study, we showed that BMCC1 was
present in the microsomal fraction of the cytoplasm and
localised to cytoplasmic granules. Initial studies revealed that
BMCC1 protein was cytoplasmic in tissue sections but failed to
provide further detail regarding isoform expression or more
specific localisation [7,8]. Here we showed that members of the
AP-2 complex co-localised with BMCC1 in cytoplasmic
granules, identifying them as clathrin-coated pits, vesicles or
endosomes. This was verified using three different antibodies
against BMCC1. BMCC1 also showed co-localisation and
juxtaposition with early sorting endosome markers Rab5 and
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EEA1 [24], as well as strong co-localisation with the recycling
endosome marker Tf.
We have shown in this study that AP-2 is not required for
BMCC1 localisation to cytoplasmic vesicles, which would
suggest that BMCC1 is not an archetypal AP-2 accessory
protein. While AP-2 is pivotal at the most early stages of
endocytic uptake of Tf and our data show localisation of
BMCC1 to early Rab5-positive endocytic vesicles, we saw that
BMCC1 knockdown does not affect Tf uptake. Moreover, our Tf
localisation data seem to indicate that BMCC1 persists and
becomes more prominent in the recycling endosome. Vesicular
trafficking is a highly complex biological process, and many
proteins appear to play multi-functional roles along different
stages of the pathway. Of particular note, while AP-2 has
traditionally been implicated in endocytic uptake at the plasma
membrane, it has more recently been shown to affect post-
endocytic trafficking and specifically to promote recycling over
degradation [35]. This certainly fits with the perinuclear
localisation of various AP-2 isoforms observed in this study.
Given the perinuclear co-localisation of BMCC1 and AP-2 and
the strong co-localisation between Tf and BMCC1, it would
appear that the BMCC1-AP2 interaction occurs during post-
endocytic uptake trafficking and targeting stages. It is thus
conceivable that BMCC1 plays roles in specific cargo transfer
from one endocytic sub-stage to the next or it may affect
pathways which determine cargo destination.
In summary, we have demonstrated that BMCC1 produces a
340 kDa protein in select prostate cancer and melanoma cell
lines. Comprehensive protein interaction mapping revealed that
BMCC1 interacts and co-localises with the AP-2 endocytic
scaffold complex in perinuclear regions of the cell. We also
observed strong co-localisation with internalised Tf at later
pulse-chase time points, which is indicative of the recycling
endosome. We have shown that BMCC1 is not required for Tf
uptake and that BMCC1 vesicular localisation is independent of
AP-2. Further studies will now be required to ascertain the
exact role of BMCC1 in post-endocytic trafficking. We have
previously shown that PCA3 is embedded in an intron of
BMCC1 [5]. The PCA3 gene is over-expressed in prostate
cancer and has been shown to be a valuable biomarker for this
disease [4]. The vesicular localisation of BMCC1described here
provides greater insight as to how this protein functions. It is
possible that BMCC1 plays an important role in some aspect of
intracellular trafficking which may in turn impact on cell
behaviour. Understanding the relationship between PCA3 and
BMCC1 will provide additional information on how these genes
function in prostate cancer.
Supporting Information
Figure S1.  BMCC1 RNA expression. A. Expression of
BMCC1-1. Expression was detected in cDNA from prostate
cancer biopsies using primers in exons 6 and 7. PCA3 was
detected in the same samples using a forward primer in exon 1
and a reverse primer across the exon 1/3 junction. Beta-2-
microglobulin was amplified as a cDNA quality and input
control. The cDNA control band for Beta-2-microglobulin is
primer dimer.
(TIF)
Figure S2.  Schematic of BMCC1 gene structure and
predicted protein domains. BMCC1 exon structure and
protein domains were collated using the online tools ExDom,
Exon-Intron Graphic Maker (wormweb.org) and Interpro:
protein sequence analysis and classification. BMCC1 isoform 1
(BMCC1-1) RNA is depicted with reference to the smaller
isoforms 2-4, BMCC1s and olfaxin (NCBI accession numbers
are noted). The obsolete BMCC1-2 is included for illustrative
purposes. The cDNA regions cloned for recombinant antigen
expression and antibody production, as well as AP-2 pull-down
(AP-2 interacting region) are indicated. The siRNA target
region is also indicated. Note that all line depictions include
intronic sequences and as such do not reflect translated
peptide/protein size.
(TIF)
Figure S3.  Expression of BMCC1 in LNCaP and melanoma
cell lines. Total cell lysates were generated from the primary
melanoma cell line A11, D11, D28, D33 and D38. 30 µg of total
lysate from each cell line was subjected to SDS-PAGE and
western blotting with rabbit anti-BMCC1 antibodies (Ab-1, Ab3).
DNA-PKcs is shown as a loading control.
(TIF)
Figure S4.  Tissue expression profiling. BMCC1 protein
expression was examined in lysates from a healthy 12 week
old male C57/B6 mouse. Tissues were harvested and lysed in
MCLB without haemolysis, and 100 µg of clarified lysate from
each tissue was resolved by SDS-PAGE on 5% or 5 to 15%
gels. Proteins were detected by western blotting or Coomassie
staining as indicated.
(TIF)
Figure S5.  Immunohistological staining for BMCC1 in
prostate cancer tissues. Benign prostatic hypertrophy (BP)
(Panels A-C) and prostatic adenocarcinoma (PCa) (Panel D
grade 3, Panel E grade 4, Panel F grade 5) tissue sections
were incubated with buffer only (Panel A) or BMCC1 Ab-3
(Panels B–F) and detected using streptavidin-biotin-peroxidase
immunostaining with diaminobenzidine. Size bar is 100µm (A,
E, F) or 50µm (B, C, D).
(TIF)
Figure S6.  Alignment of AP-2A1 and AP-2A2. AP-2A1 and
AP-2A2 protein sequences obtained from the NCBI were
aligned using Clustal W (default settings). Peptides identified
by MALDI MS/MS in our purification of BMCC1 interactors are
indicated, identified by sample number- peptide number with
summary statistics for each peptide in Supp Table 2.
(TIF)
Figure S7.  Expression of BMCC1 throughout the cell
cycle. A. Sychronised LNCaP cells with a single
aphidicolin block (5 µg/mL) for 36 h. Cells were released by
washing in drug-free media and fixed at intervals after
aphidicolin removal. Fixed coverslips were kept in PBS at 4 °C
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until all time points had been collected. Cells were then stained
for BMCC1 (rabbit Ab-1 antibody) and detected with donkey
anti-rabbit Alexafluor488. Cells were counterstained with
Hoechst, mounted in moviol and analysed on a wide-field
microscope (x63 objective). B. Inhibition of S-phase
progression assessed by BrdU incorporation. Normally
cycling or aphidicolin blocked cells were incubated with 100 µM
BrdU for 2 h in growth media before fixation. BrdU
incorporation was detected in fixed, alkaline denatured cells
using rat anti-BrdU and donkey anti-rat Alexafluor 488.
(TIF)
Figure S8.  BMCC1 colocalisation and juxtaposition with
early endosomal marker EEA1. LNCaP cells were stained for
sheep anti- BMCC1 and mouse anti- EEA1, and detected with
anti-sheep Alexafluor594 and anti mouse- Alexafluor 488. The
white arrow highlights an area of clear co-localisation between
the two proteins and the yellow arrow highlights an EEA1-
negative BMCC1-positive vesicle. Scale bar is 10 µm.
(TIF)
Table S1.  Cloning, PCR and siRNA primer sequences.
(TIF)
Table S2.  MALDI TOF/TOF data summary- BMCC1
interactions.
(TIF)
Table S3.  Attribution of identified peptides between high-
homology AP-2A1 and AP-2A2.
(TIF)
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